A graduate of Princeton University with a bachelor of arts degree in English, Dr. Bilenker attended medical school at the Johns Hopkins School of Medicine. He then completed his postgraduate training in internal medicine and medical oncology at the Hospital of the University of Pennsylvania. During this time, Dr. Josh Bilenker participated in designing Phase 1 and II clinical studies for investigational cancer therapies. Following his academic training, Dr. Bilenker served as a medical officer at the FDA. He then spent seven years as an investment professional at a NYC-based life sciences venture firm. The founder of oncology-focused therapeutics company Loxo Oncology, Inc., Dr. Bilenker led the company as president and chief executive officer from 2013 to 2019. In late 2019, Dr. Bilenker, along with the senior management team of Loxo Oncology, assumed responsibility for oncology R&D at Eli Lilly and Company. In addition to his executive experience, Dr. Bilenker holds the title of senior associate with the Department of Health Policy and Management at the Johns Hopkins University Bloomberg School of Public Health. Dr. Bilenker is a member of multiple professional organizations related to cancer research, including the American Society of Clinical Oncology, the American Association for Cancer Research and the American Society of Hematology.